NCT03434873

Brief Summary

This work is intended to assess the effect of repetitive magnetic stimulation on the sacral roots versus repetitive magnetic stimulation on motor cortex in multiple sclerosis patients with the lower urinary tract dysfunction.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable multiple-sclerosis

Timeline
Completed

Started Oct 2014

Shorter than P25 for not_applicable multiple-sclerosis

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2014

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

February 2, 2018

Completed
13 days until next milestone

First Posted

Study publicly available on registry

February 15, 2018

Completed
Last Updated

February 15, 2018

Status Verified

February 1, 2018

Enrollment Period

6 months

First QC Date

February 2, 2018

Last Update Submit

February 14, 2018

Conditions

Keywords

magnetic stimulation, multiple sclerosis

Outcome Measures

Primary Outcomes (5)

  • Change from baseline King's Health QoL questionnaire score after treatment

    questionnaire evaluates the impact of lower urinary tract symptoms on patient's quality of life. High scores represent a worse quality of life, with no cut-off values.

    1-7 days after treatment

  • Change from baseline Post-void residual urine after treatment

    Measured by ultrasound It is the volume of urine left in the bladder at the completion of micturition Measured in milliliters (mL)

    1-7 days after treatment

  • Change from baseline Maximum Cystometric Capacity (MCC) after treatment

    Measured by urodynamic evaluation Measured in millimeters (mL) It is the volume at which the patient states that he/she can no longer delay micturition because of strong desire to void or urgency

    1-7 days after treatment

  • Change from baseline Maximum Flow Rate (Qmax) after treatment

    Measured by urodynamic evaluation Measured in milliliters per second (mL/sec) It is the maximum measured value of the flow rate

    1-7 days after treatment

  • Change from baseline Detrusor pressure at maximum flow rate (Pdet @Qmax) after treatment

    Measured by urodynamic evaluation Measured in centimeter water (cmH2O) It represents the effect of the active and/or passive forces generated by the detrusor muscle

    1-7 days after treatment

Study Arms (2)

Sacral magnetic stimulation

ACTIVE COMPARATOR

Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over sacral roots

Other: magnetic stimulation

Cortical magnetic stimulation

ACTIVE COMPARATOR

Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks, over motor cortex

Other: magnetic stimulation

Interventions

Twenty trains of 50 stimuli at 5 Hz (train duration: 10 seconds) separated by a 40-second pause were delivered for a total of 1000 pulses, once a day for four consecutive days for two weeks

Cortical magnetic stimulationSacral magnetic stimulation

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Multiple Sclerosis patients (diagnosed by McDonald criteria 2010) with lower urinary tract dysfunction
  • Adults more than 18 years
  • Unresponsiveness to medical treatment
  • Urodynamic diagnosis of detrusor overactivity and/or detrusor underactivity and/or detrusor-sphincter dyssynergia

You may not qualify if:

  • Urinary tract infections
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Multiple SclerosisLower Urinary Tract Symptoms

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesUrological ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

February 2, 2018

First Posted

February 15, 2018

Study Start

October 1, 2014

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

February 15, 2018

Record last verified: 2018-02